Research ArticleNEUROPHARMACOLOGY
Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor
D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. Srinivasan, B. Wang, B. J. Robertson, C. T. Polson, J. Wang, S. B. Roberts, J. P. Hendrick, J. J. Anderson, J. K. Loy, R. Denton, T. A. Verdoorn, D. W. Smith and K. M. Felsenstein
Journal of Pharmacology and Experimental Therapeutics February 2005, 312 (2) 635-643; DOI: https://doi.org/10.1124/jpet.104.075408
D. M. Barten
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
V. L. Guss
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
J. A. Corsa
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
A. Loo
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
S. B. Hansel
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
M. Zheng
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
B. Munoz
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
K. Srinivasan
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
B. Wang
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
B. J. Robertson
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
C. T. Polson
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
J. Wang
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
S. B. Roberts
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
J. P. Hendrick
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
J. J. Anderson
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
J. K. Loy
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
R. Denton
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
T. A. Verdoorn
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
D. W. Smith
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
K. M. Felsenstein
Bristol-Myers Squibb, Wallingford, Connecticut (D.M.B., V.L.G., J.A.C., A.L., S.B.H., M.Z., B.J.R., C.T.P., J.W., S.B.R., J.P.H., J.K.L., R.D., T.A.V., D.W.S., K.M.F.); Vertex Pharmaceuticals, Cambridge, Massachusetts (A.L.); SIBIA Neurosciences, Inc., La Jolla, California (B.M., B.W., J.J.A.); Merck Research Laboratories, San Diego, California (B.M., B.W.); Neurogenetics Inc., La Jolla, California (K.S.); IntraCellular Therapies, New York, New York (J.P.H.); Cypress Bioscience, Inc., San Diego, California (J.J.A.); Pfizer, Groton, Connecticut (J.K.L.); Algos Therapeutics, Inc., St. Paul, Minnesota (T.A.V.); and Johnson and Johnson PRD, Spring House, Pennsylvania (K.M.F.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleNEUROPHARMACOLOGY
Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor
D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. Srinivasan, B. Wang, B. J. Robertson, C. T. Polson, J. Wang, S. B. Roberts, J. P. Hendrick, J. J. Anderson, J. K. Loy, R. Denton, T. A. Verdoorn, D. W. Smith and K. M. Felsenstein
Journal of Pharmacology and Experimental Therapeutics February 1, 2005, 312 (2) 635-643; DOI: https://doi.org/10.1124/jpet.104.075408
Research ArticleNEUROPHARMACOLOGY
Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor
D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. Srinivasan, B. Wang, B. J. Robertson, C. T. Polson, J. Wang, S. B. Roberts, J. P. Hendrick, J. J. Anderson, J. K. Loy, R. Denton, T. A. Verdoorn, D. W. Smith and K. M. Felsenstein
Journal of Pharmacology and Experimental Therapeutics February 1, 2005, 312 (2) 635-643; DOI: https://doi.org/10.1124/jpet.104.075408
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement